21 CFR 3.9
§ 3.9 Effect of letter of designation.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 3.9, § 3.9 Effect of letter of designation, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/83001
- Permanent ID
ys:prov:83001@1- SHA-256
d60d48e2e355428776a5e115c6e4e6e08b700c01091a4afe4832456291d36a5e
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) The letter of designation constitutes an agency determination that is subject to change only as provided in paragraph (b) of this section.
(b) The product jurisdiction officer may change the designated agency component with the written consent of the sponsor, or without its consent to protect the public health or for other compelling reasons. A sponsor shall be given 30 days written notice of any proposed nonconsensual change in designated agency component. The sponsor may request an additional 30 days to submit written objections, not to exceed 15 pages, to the proposed change, and shall be granted, upon request, a timely meeting with the product jurisdiction officer and appropriate center officials. Within 30 days of receipt of the sponsor's written objections, the product jurisdiction officer shall issue to the sponsor, with copies to appropriate center officials, a written determination setting forth a statement of reasons for the proposed change in designated agency component. A nonconsensual change in the designated agency component requires the concurrence of the Principal Associate Commissioner.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.